Insulet CORP 10-Q quarterly reports

Insulet Corporation reported a 33.9% increase in total revenue for the first quarter of 2026, driven by strong performance of its Omnipod 5 system and international expansion.

Insulet Corporation reported robust third-quarter revenue growth of 29.9% to $706.3 million, driven by strong Omnipod product sales and international expansion.

Insulet Corporation announced robust Q2 2025 revenue growth and improved gross margins, despite a net income decline driven by debt extinguishment costs and prior-year tax benefits.

Insulet Corporation's Q1 2025 revenue increased by 28.8% year-over-year, primarily driven by increased sales volume of the Omnipod platform and drug delivery systems.

Insulet Corporation's Q3 2024 results show significant revenue growth, driven by increased adoption of the Omnipod 5 system and international expansion.

Insulet Corporation's Q2 2024 results show significant revenue growth and a substantial increase in net income, primarily driven by the adoption of the Omnipod 5 system.

Insulet Corporation's first quarter 2024 results show significant revenue growth and improved profitability, driven by increased adoption of the Omnipod 5 system.